1. Cell Cycle/DNA Damage Anti-infection Autophagy
  2. DNA/RNA Synthesis Nucleoside Antimetabolite/Analog HSV Autophagy
  3. Cytarabine hydrochloride

Cytarabine hydrochloride  (Synonyms: Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; Ara-C hydrochloride)

Cat. No.: HY-13605A Purity: 99.67%
SDS COA Handling Instructions

Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine hydrochloride has antiviral effects against HSV.

For research use only. We do not sell to patients.

Cytarabine hydrochloride Chemical Structure

Cytarabine hydrochloride Chemical Structure

CAS No. : 69-74-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
100 mg USD 60 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 55 publication(s) in Google Scholar

Other Forms of Cytarabine hydrochloride:

Top Publications Citing Use of Products

54 Publications Citing Use of MCE Cytarabine hydrochloride

WB

    Cytarabine hydrochloride purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Mar 29.  [Abstract]

    TF-1 clones are incubated with 2 µM Cytarabine (araC) for up to 10 or 12 h, and cleaved caspase-3 is detected by immunoblot analysis.

    View All HSV Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine hydrochloride has antiviral effects against HSV.

    IC50 & Target

    IC50: 16 nM (DNA synthesis)

    Cellular Effect
    Cell Line Type Value Description References
    143B IC50
    16.88 μM
    Compound: Cytarabine
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    [PMID: 27073055]
    143B IC50
    2.06 μM
    Compound: Cytarabine
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    [PMID: 27073055]
    A549 GI50
    0.2 μM
    Compound: Ara-C
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    A549 IC50
    0.83 μM
    Compound: ara-C
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    A549 IC50
    1.2 μM
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    A549 IC50
    1.75 μM
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    A549 IC50
    1.9 μM
    Compound: 2, Ara-C
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 24956556]
    A549 IC50
    1.9 μM
    Compound: 1, ara-C
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    [PMID: 19691349]
    A549 IC50
    3.47 μM
    Compound: ara-C
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    A549 IC50
    49.27 μg/mL
    Compound: CAR
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 35963130]
    A549 IC50
    620 μM
    Compound: cytarabine
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    [PMID: 17419604]
    B16 IC50
    30.62 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    B16 IC50
    49.22 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    BALL-1 GI50
    0.08 μM
    Compound: Ara-C
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    Bel-7402 IC50
    34.2 μM
    Compound: Ara-C
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    [PMID: 20692841]
    CCRF S-180 ED50
    0.2 μM
    Compound: ara-C
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    CCRF S-180 IC50
    25.43 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    CCRF S-180 IC50
    40.33 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    CCRF-CEM IC50
    0.001 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    [PMID: 19674903]
    CCRF-CEM EC50
    0.005614 μM
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    CCRF-CEM IC50
    0.006 μM
    Compound: Ara-C
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    [PMID: 22582991]
    CCRF-CEM ED50
    0.006 μM
    Compound: ara-C
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    CCRF-CEM EC50
    0.0228 μM
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    CCRF-CEM IC50
    0.024 μM
    Compound: cytarabine
    Cytotoxicity against human CEM cells after 2 days
    Cytotoxicity against human CEM cells after 2 days
    [PMID: 19910080]
    CCRF-CEM IC50
    0.024 μM
    Compound: ara-C, cytarabine
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    [PMID: 20000418]
    CCRF-HSB-2 IC50
    0.017 μg/mL
    Compound: AraC
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    [PMID: 18819815]
    CCRF-HSB-2 IC50
    0.017 μg/mL
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    [PMID: 18723355]
    CCRF-HSB-2 IC50
    0.047 μg/mL
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    [PMID: 17644399]
    CCRF-HSB-2 IC50
    0.047 μg/mL
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    [PMID: 17962027]
    CCRF-HSB-2 IC50
    0.15 μM
    Compound: ara-C
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    [PMID: 17049252]
    H22 IC50
    25.98 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    H22 IC50
    37.82 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    HCT-116 IC50
    0.1 μM
    Compound: Ara-C
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    HCT-116 GI50
    0.12 μM
    Compound: Ara-C
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    HCT-116 IC50
    2.42 μM
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    HCT-116 IC50
    4.4 μM
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    HCT-116 IC50
    5.3 μM
    Compound: 2, Ara-C
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    [PMID: 24956556]
    HCT-116 IC50
    5.3 μM
    Compound: 1, ara-C
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    [PMID: 19691349]
    HeLa ED50
    0.05 μg/mL
    Compound: AraC
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    [PMID: 178873]
    HeLa GI50
    0.18 μM
    Compound: Ara-C
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    HeLa IC50
    0.26 μM
    Compound: ara-C, cytarabine
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    [PMID: 20000418]
    HeLa IC50
    3.54 μM
    Compound: ara-C
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    HeLa IC50
    3.54 μM
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    [PMID: 27073055]
    HeLa IC50
    3.54 μM
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    [PMID: 23867603]
    HeLa IC50
    3.54 μM
    Compound: ara-C
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    HeLa IC50
    464.433 μM
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 19321234]
    HeLa S3 ED50
    2.13 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    HepG2 IC50
    0.2 μM
    Compound: Ara-C
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 20692841]
    HepG2 IC50
    2.86 μM
    Compound: ara-C
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    HepG2 IC50
    2.86 μM
    Compound: Cytarabine
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    [PMID: 27073055]
    HepG2 IC50
    2.86 μM
    Compound: ara-C
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    HepG2 IC50
    26.23 μM
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    HepG2 IC50
    38.1 μM
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    HL-60 IC50
    0.049 μM
    Compound: Ara-C
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    [PMID: 22582991]
    HL-60 IC50
    0.118 μM
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    [PMID: 19321234]
    HL-60 EC50
    0.6572 μM
    Compound: cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    HL60/MX2 EC50
    0.2612 μM
    Compound: cytarabine
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    HT-29 IC50
    66 nM
    Compound: cytosine arabinoside
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    [PMID: 2778449]
    HUVEC GI50
    0.23 μM
    Compound: Ara-C
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    [PMID: 22264170]
    K562 IC50
    0.05 μM
    Compound: 2, Ara-C
    Cytotoxicity against human K562 cells by SRB assay
    Cytotoxicity against human K562 cells by SRB assay
    [PMID: 24956556]
    K562 IC50
    0.05 μM
    Compound: 1, ara-C
    Cytotoxicity against human K562 cells by sulforhodamine B method
    Cytotoxicity against human K562 cells by sulforhodamine B method
    [PMID: 19691349]
    K562 IC50
    14 μM
    Compound: Ara-C
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    [PMID: 22582991]
    K562 IC50
    24.29 μM
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    K562 IC50
    33.5 μM
    Compound: Ara-C
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    [PMID: 20692841]
    K562 IC50
    43.61 μM
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    KB IC50
    0.14 μg/mL
    Compound: Ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    [PMID: 18055068]
    KB IC50
    0.23 μg/mL
    Compound: Ara-C
    Antitumor activity against human KB cells by modified MTT assay
    Antitumor activity against human KB cells by modified MTT assay
    [PMID: 17644399]
    KB IC50
    0.23 μg/mL
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    [PMID: 17962027]
    KB IC50
    0.42 μg/mL
    Compound: AraC
    Growth inhibition of human KB cells by MTT method
    Growth inhibition of human KB cells by MTT method
    [PMID: 18819815]
    KB IC50
    0.7 μM
    Compound: ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    [PMID: 17049252]
    KB IC50
    0.73 μg/mL
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    [PMID: 18723355]
    KB IC50
    0.99 μg/mL
    Compound: Cytarabine
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    [PMID: 21945463]
    KB ED50
    2.84 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    KB IC50
    4.07 μM
    Compound: ara-C
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    KB IC50
    4.07 μM
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    [PMID: 27073055]
    KB IC50
    4.07 μM
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    [PMID: 23867603]
    KB IC50
    4.07 μM
    Compound: ara-C
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    L02 IC50
    0.17 μM
    Compound: ARA
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 29886320]
    L02 IC50
    0.21 μM
    Compound: ARA
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    [PMID: 30852384]
    L1210 IC50
    0.0004 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    [PMID: 19674903]
    L1210 IC50
    0.024 μM
    Compound: cytarabine
    Cytotoxicity against mouse L1210 cells after 2 days
    Cytotoxicity against mouse L1210 cells after 2 days
    [PMID: 19910080]
    L1210 IC50
    0.024 μM
    Compound: ara-C, cytarabine
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    [PMID: 20000418]
    L1210 ED50
    0.05 μM
    Compound: ara-C
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    L1210 ED50
    0.1 μM
    Compound: ara-C
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    [PMID: 118258]
    L1210 ED50
    0.19 μM
    Compound: ara-C
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    [PMID: 3968680]
    L1210 IC50
    103 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    [PMID: 19674903]
    L1210 ED50
    2.76 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    MCF7 IC50
    > 20 μM
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    [PMID: 35665692]
    MCF7 IC50
    ≥ 100 μM
    Compound: Ara-C
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    MCF7 IC50
    0.004 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    [PMID: 19674903]
    MCF7 IC50
    0.04 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    [PMID: 19674903]
    MCF7 IC50
    0.93 μg/mL
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    [PMID: 21945463]
    MCF7 IC50
    3.82 μM
    Compound: Cytarabine
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    [PMID: 27073055]
    MCF7 IC50
    3.82 μM
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    [PMID: 23867603]
    MCF7 IC50
    3.82 μM
    Compound: ara-C
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    MDA-MB-231 IC50
    1.37 μM
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    MDA-MB-231 IC50
    10.49 μM
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    MES-SA IC50
    1.7 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    [PMID: 19674903]
    MOLT-3 ED50
    2.67 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    MOLT-4 IC50
    1 μM
    Compound: Ara-C
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    MV4-11 IC50
    3.36 μM
    Compound: AraC
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    [PMID: 20153646]
    NCI-H460 IC50
    0.1 μM
    Compound: Ara-C
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    NHDF IC50
    4.99 μM
    Compound: ara-C
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    NHDF IC50
    4.99 μM
    Compound: ara-C
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    NUGC-3 GI50
    0.25 μM
    Compound: Ara-C
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    P388 ED50
    0.02 μM
    Compound: ara-C
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    P388 IC50
    1233 nM
    Compound: cytosine arabinoside
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    [PMID: 2778449]
    PC-3 IC50
    0.81 μM
    Compound: ara-C
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    PC-3 IC50
    48.4 μM
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    PC-3 IC50
    50.51 μM
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    PC-3 IC50
    55.9 μM
    Compound: 2, Ara-C
    Cytotoxicity against human PC3 cells by SRB assay
    Cytotoxicity against human PC3 cells by SRB assay
    [PMID: 24956556]
    PC-3 IC50
    55.9 μM
    Compound: 1, ara-C
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    [PMID: 19691349]
    RS4-11 IC50
    0.26 μM
    Compound: AraC
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    [PMID: 20153646]
    SF-268 IC50
    7.68 nM
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells by MTT assay
    Cytotoxicity against human SF268 cells by MTT assay
    [PMID: 19345581]
    SF-268 IC50
    7.68 μM
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    [PMID: 20356655]
    SK-BR-3 IC50
    0.87 μM
    Compound: ara-C
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    SK-HEP1 IC50
    1.8 μM
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    SK-HEP1 IC50
    2.12 μM
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    SK-OV-3 IC50
    0.99 μM
    Compound: ara-C
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    SMMC-7721 IC50
    0.013 μM
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 29886320]
    SMMC-7721 IC50
    0.0271 μM
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    [PMID: 30852384]
    SNU-638 IC50
    0.15 μM
    Compound: 2, Ara-C
    Cytotoxicity against human SNU638 cells by SRB assay
    Cytotoxicity against human SNU638 cells by SRB assay
    [PMID: 24956556]
    SNU-638 IC50
    0.15 μM
    Compound: 1, ara-C
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    [PMID: 19691349]
    SNU-638 IC50
    1.08 μM
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    SNU-638 IC50
    3.98 μM
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    SW1573 IC50
    10500 μM
    Compound: cytarabine
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    [PMID: 17419604]
    SW480 ED50
    3.42 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    SW-620 IC50
    30 μM
    Compound: Ara-C
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    T47D IC50
    2.7 μM
    Compound: 1, ara-C
    Cytotoxicity against human T47D cells by sulforhodamine B method
    Cytotoxicity against human T47D cells by sulforhodamine B method
    [PMID: 19691349]
    T47D IC50
    2.72 μM
    Compound: 2, Ara-C
    Cytotoxicity against human T47D cells by SRB assay
    Cytotoxicity against human T47D cells by SRB assay
    [PMID: 24956556]
    U-87MG ATCC CC50
    0.19 μM
    Compound: 16
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    [PMID: 35123007]
    U-87MG ATCC IC50
    0.85 μM
    Compound: ara-C
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    U-87MG ATCC IC50
    2.88 μM
    Compound: ara-C
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    U-937 IC50
    0.002 μM
    Compound: Cytarabine
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    [PMID: 30954427]
    Vero EC50
    1.6 μg/mL
    Compound: Ara-C
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    [PMID: 12444692]
    Vero EC50
    3 μg/mL
    Compound: Ara-C
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    [PMID: 12444692]
    Vero CC50
    4.8 μg/mL
    Compound: Ara-C
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    [PMID: 12444692]
    WI-38 IC50
    > 100 μg/mL
    Compound: CAR
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    [PMID: 35963130]
    In Vitro

    Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM[1]. Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity[3]. Cytarabine is highly effective against acute leukaemias, which causes the chCytarabineteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    279.68

    Formula

    C9H14ClN3O5

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N.Cl

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (178.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.5755 mL 17.8776 mL 35.7551 mL
    5 mM 0.7151 mL 3.5755 mL 7.1510 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (8.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.67%

    References
    Animal Administration
    [3]

    Pregnant rats are injected intraperitoneally (i.p.) with 250 mg/kg of Cytarabine on Day 13 of gestation (GD13). Under the conditions of this experiment, congenital anomalies and growth retardation are detected at a high rate in perinatal fetuses, although the incidence of fetal death is not markedly increased. At 1, 3, 6, 9, 12, 24, and 48 h after the treatment, six dams each are killed by heart puncture under ether anesthesia, and the placentas are collected. As controls, six pregnant rats are injected i.p. with an equivalent volume of PBS on GD13 and killed at the same time point as Cytarabine-treated groups. Of the six dams obtained at each time point, three are used for histopathological analyses and three for reverse transcription-polymerase chain reaction (RT-PCR) analysis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5755 mL 17.8776 mL 35.7551 mL 89.3879 mL
    5 mM 0.7151 mL 3.5755 mL 7.1510 mL 17.8776 mL
    10 mM 0.3576 mL 1.7878 mL 3.5755 mL 8.9388 mL
    15 mM 0.2384 mL 1.1918 mL 2.3837 mL 5.9592 mL
    20 mM 0.1788 mL 0.8939 mL 1.7878 mL 4.4694 mL
    25 mM 0.1430 mL 0.7151 mL 1.4302 mL 3.5755 mL
    30 mM 0.1192 mL 0.5959 mL 1.1918 mL 2.9796 mL
    40 mM 0.0894 mL 0.4469 mL 0.8939 mL 2.2347 mL
    50 mM 0.0715 mL 0.3576 mL 0.7151 mL 1.7878 mL
    60 mM 0.0596 mL 0.2980 mL 0.5959 mL 1.4898 mL
    80 mM 0.0447 mL 0.2235 mL 0.4469 mL 1.1173 mL
    100 mM 0.0358 mL 0.1788 mL 0.3576 mL 0.8939 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cytarabine hydrochloride
    Cat. No.:
    HY-13605A
    Quantity:
    MCE Japan Authorized Agent: